Scientists hunt for Cancer-Fighting immune cells in patients
NCT ID NCT05354765
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is collecting blood samples from 300 cancer patients to look for immune cells that target tumors. Researchers want to understand how the immune system responds to cancer and treatments. The study does not test a new drug or therapy, but aims to gather knowledge that could help future research.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this could help researchers better understand how the immune system fights cancer, potentially guiding future treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It is early-stage research and may not lead directly to new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2022
- Expected to finish
-
Sep 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Patient aged 18 or over, 2. Patient presenting an invasive tumor pathology (proven or suspected). The location and / or stage of which are defined for each cohort through an amendment to the protocol, 3. Patient treated with immune-modulators or other treatments likely to modify immunological parameters, 4. Suspicion of immune mediated response or toxicities (assessed by the immunologists), 5. Peripheral venous capital usable and compatible with the realization of 2 venous accesses for lymphapheresis and absence of cardiovascular problem (heart failure, arrhythmia ...), per investigator assessement, 6. Total circulating lymphocytes\> 1000 / mm3, 7. Availability of DNA and RNA from the tumor, 8. Information to the patient and signature of informed consent or his legal representative, 9. Affiliated with a social security scheme or such a scheme. Exclusion Criteria: 1. Inability to undergo study follow-up for geographical, social or psychological reasons, 2. Infection with HIV or hepatitis B or C viruses, 3. Patients on high dose corticosteroid treatment (\> 1 mg / kg continuously), 4. Any concomitant serious illness that may interfere with participation in the study or significantly affect the results of the study (pulmonary, heart or liver disease), 5. Contraindication to performing lymphapheresis (coagulation disorder, cardiovascular problems, venous access, hypocalcemia, psychological inability to undergo extracorporeal circulation, cachexia, etc.), 6. Pregnant patient or of childbearing age without effective contraception, 7. Persons deprived of their liberty, under guardianship or legal protection.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Institut Curie
RECRUITINGParis, 75005, France
-
Institut Curie
RECRUITINGSaint-Cloud, 92210, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Évaluation de la détresse post-traumatique relative au cancer dans l'année suivant le diagnostic chez les patients et les aidants et identification de leurs attentes envers un accompagnement personnalisé
- Development and pilot implementation of a novel remote patient monitoring program for cancer patients initiating cancer-directed therapy: the SHIELD (Smart health integration for early life-saving detection)
- The promoting resilience in stress Management-Social needs (PRISM-SN) intervention for adolescents and young adults with cancer: a randomized controlled trial
- An equity focused intervention to improve utilization of guideline concordant extended venous thromboembolism prophylaxis after major cancer surgery
- The effect of gamified sleep hygiene education on sleep quality and fatigue levels in chemotherapy patients
- Can 10 minutes of breathing ease Chemotherapy's toll?